Oct. 24 at 5:23 PM
$IWMW $PNQI $TDOC $BAC
Teladoc: Differentiated & Massively Undervalued
Bank of America calls Teladoc a differentiated asset due to:
• Unmatched scale (90M+ members, global reach)
• High-value tuck-ins (UpLift, Telecare) adding mental health & international growth
Current
$1.5B market cap is deeply undervalued at 0.6x sales — vs. historical peaks and peers.
Bull case: Execution on chronic care, AI, and acquisitions drives 10–15% revenue growth →
$40B+ market cap (2021 high) =
$225+ per share (26x current price).
Even a partial recovery to
$20B cap = ~
$113/share (13x upside).
Bottom line: Teladoc’s moat + growth runway = asymmetric upside for patient investors.